Beigene Ltd (NASDAQ:BGNE) traded up 1.4% during trading on Wednesday . The company traded as high as $28.24 and last traded at $27.68, with a volume of 78,948 shares changing hands. The stock had previously closed at $27.29.

A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded Beigene from a “sell” rating to a “hold” rating in a research report on Tuesday, July 19th. Cowen and Company reiterated a “buy” rating on shares of Beigene in a research report on Monday, June 6th. One analyst has rated the stock with a hold rating and four have given a buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $39.67.

The company has a 50 day moving average of $28.41 and a 200-day moving average of $28.74. The company’s market cap is $622.22 million.

Beigene (NASDAQ:BGNE) last posted its quarterly earnings results on Wednesday, August 10th. The company reported ($0.73) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.68) by $0.05. The business earned $0.40 million during the quarter, compared to the consensus estimate of $2.08 million. The company’s revenue for the quarter was down 71.4% on a year-over-year basis. Equities research analysts forecast that Beigene Ltd will post ($3.17) earnings per share for the current year.

BeiGene, Ltd. is a biopharmaceutical company. The Company is engaged in the discovery and development of molecularly targeted and immuno-oncology drugs for the treatment of cancer. It is developing its product candidate, BGB-3111, a potent and selective small molecule Bruton’s tyrosine kinase (BTK) inhibitor, as a monotherapy and in combination with other therapies for the treatment of a range of lymphomas.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.